Latest revenue
$5.0M
as of 2023-06-30
Latest net income
$79.2K
as of 2023-06-30
Net margin
1.6%
as of 2023-06-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Wholesale-Medical, Dental & Hospital Equipment & Supplies (3 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think FZMD is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.2M
- Enterprise value
- $2.3M
- P/E (trailing)
- 0.7×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 73.9M
5-year trend
What this company does
Overview We are a manufacturer and national distributor of medical devices in the United States. We provide a broad portfolio of orthopedic implants including: • Foot and Ankle: internal and external fixation products; • Orthopedics: upper and lower extremity plating and total joint reconstruction implants; • Sports Medicine: soft tissue fixation and augmentation for sports medicine procedures; • Spine: full spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, we refer to these bulleted products as “Orthopedic Implants”). We also provide a wide array of osteo-biologics and regenerative products, which include human allografts, tendons, synthetic…
AI summary unavailable — showing raw filing excerpt
Generated from FZMD's filing dated 2023-04-14
Key risks
ITEM 1A. RISK FACTORS. Our business and an investment in our securities are subject to a variety of risks. The following risk factors describe some of the most significant events, facts, and circumstances that could have a material adverse effect upon our business, financial condition, results of operations, ability to implement our strategies and business plans, and the market price for our securities. Many of these events are outside of our control. If any of these events occur, our business, financial condition, or results of operations may be materially adversely affected, the trading price of our Common Stock could decline and investors in our Common Stock could lose all or part of…
AI summary unavailable — showing raw filing excerpt
Generated from FZMD's filing dated 2023-04-14
Profitability
Gross margin
61.9%
5.9%Operating margin
-4.4%
59.4%Net margin
16.6%
313.6%Return on equity
-996.6%
2254.0%Return on assets
15.7%
280.7%Leverage
Debt / equity
-64.58×
919.5%Long-term debt / equity
-0.64×
1004.0%Debt / assets
101.6%
14.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q2 2023 2023-06-30 | $5.0M | — | $79.2K | — | 1.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Medical, Dental & Hospital Equipment & Supplies · SIC 5047
Your notes
Keep private notes on FZMD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for FZMD in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns FZMD
No institutional holdings on file for FZMD yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once FZMD's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.